The Ewing's sarcoma family of tumours (ESFT) are small round cell tumours characterized by the non-random EWS-ETS gene rearrangements. We have previously demonstrated that ESFT are highly sensitive to fenretinide-induced death, effected in part through a reactive oxygen species (ROS)-dependent pathway. Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG. This decrease in cell death was independent of the level of ROS produced following exposure to fenretinide, but was effected through EWSFli1-dependent modulation of p38 MAPK activity. Furthermore, inhibition of p38 MAPK activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38
Introduction
Fenretinide is a retinamide with both chemopreventative (Zanardi et al., 2006) and chemotherapeutic properties in a range of adult malignancies (Chiesa et al., 2005; Simeone et al., 2005) , and has manageable toxicity in adults (Formelli et al., 1993; Pienta et al., 1997) and children (Garaventa et al., 2003; Villablanca et al., 2006) . We have reported previously that fenretinide induces cell death in the Ewing's sarcoma family of tumours (ESFT) in vitro and reduces ESFT growth in vivo (Myatt et al., 2005) , suggesting it may represent a novel therapeutic strategy for the treatment of this aggressive tumour of bone and soft tissue (Burchill, 2003) .
ESFT are characterized by the presence of EWS-ETS gene rearrangements, arising from non-random gene translocations fusing the 5 0 portion of the EWS gene located at 22q12 to a series of ETS gene family members. In 85% of cases, the gene fusion is between EWS and Fli1 on chromosome 11 (Delattre et al., 1994) . The EWS-ETS fusion proteins are necessary for the induction and maintenance of the ESFT malignant phenotype, demonstrated by EWS-Fli1 induced transformation of NIH-3T3 cells and murine primary bonederived cells (May et al., 1993; Thompson et al., 1999; Castillero-Trejo et al., 2005; Smith et al., 2006) and reduced ESFT cell tumorigenicity (Wu et al., 2001; Malone et al., 2003; Hu-Lieskovan et al., 2005a) and cell proliferation (Dohjima et al., 2003; Chansky et al., 2004) following decreased expression of EWS-Fli1 using antisense oligonucleotides or siRNA. We therefore hypothesized that the increased sensitivity of these cells to fenretinide may be dependent on expression of specific EWS-ETS fusion proteins. To test this hypothesis we have investigated the activity of fenretinide in ESFT cells with decreased expression of EWS-Fli1.
In this study, we provide for the first time evidence that downregulation of EWS-Fli1 expression attenuates the sensitivity of ESFT to fenretinide, and that this is effected through modulation of the p38 MAPK pathway. Moreover, we demonstrate that fenretinide-induced mitochondrial depolarization, cytochrome c release and caspase cleavage are dependent on phosphorylation of p38 MAPK and EWS-Fli1 expression.
Results
Decreased EWS-Fli1 expression using siRNA siBP1 failed to reduce EWS-Fli1 expression in any cell line ( Figure 1 ). However, siRF1 reduced EWS-Fli1 type 1 expression in TC-32 and A673 cells, siBP2 reduced EWS-Fli1 expression in A673 but not TC-32 cells ( Figure 1 ). siCON had no effect on EWS-Fli1 expression, and siRF1 and siBP2 had no effect on expression of EWS-ERG in TTC-466 cells (results not shown). TTC-466 (which expresses EWS-ERG) was used as a negative control. Expression of EWS mRNA was similar in A673, TC-32 and TTC-466 cells. Electroporation with siCON, buffer alone, siRF1 or siBP2 had no effect on EWS mRNA expression detected by quantitative reverse transcriptase (RT)-PCR; the difference in expression for all cells treated according to different conditions was always o1 CT value. Similarly, electroporation with siCON, buffer alone, siRF1 or siBP2 had no effect on Fli1 mRNA expression in any cell line studied; difference in expression was o1 CT value across all cells. We anticipated that siRNA targeting the fusion breakpoint might be a more specific inhibitor of EWSFli1 expression than siRNA against Fli1; however, using real-time RT-PCR, we demonstrated that siRNA targeting both the breakpoint and the Fli1 region of EWS-Fli1 had no effect on EWS or Fli1 expression. The lack of inhibition of Fli1 expression by siRF1 suggests differences in the secondary structure of wild-type Fli1 and EWS-Fli1 mRNAs.
Decreased EWS-Fli1 expression attenuates fenretinideinduced cell death Cells were untreated (control), electroporated in buffer, or with 100 nM of siCON or siRNAs designed to knock down expression of EWS-Fli1. Sixteen hours after electroporation, cells were treated with 0.7-10 mM of fenretinide and viable cell number determined 24 h later. Fenretinide induced a dose-dependent reduction in A673 viable cell number in the non-electroporated control, buffer and siCON-treated cells (Figure 2a) . However, the decrease in A673 viable cell number was significantly reduced following treatment of cells electroporated with siBP2 or siRF1 (Po0.05). The IC 50 values for siCON-, siBP2-and siRF1-electroporated cells were 2.3, 5.9 and 6.1 mM respectively. Similarly in TC-32 cells, electroporation with siRF1 reduced the effect of fenretinide (0.7-3.0 mM) on viable cell number (Po0.001); IC 50 values for siCON-and siRF1-treated TC-32 cells were 1.6 and 9.8 mM respectively (Figure 2b ). Electroporation of TC-32 cells with siBP2, which did not knock down EWS-Fli1 expression, had no effect on fenretinide-induced cell death. Electroporation of TTC-466 cells (EWS-ERG expressing cells) with siCON, siBP2 or siRF1 had no effect on fenretinide-induced decrease in viable cell number (0.7-10 mM; 24h; Figure 2c ). This supports the hypothesis that the reduced effect of fenretinide on viable cell number observed in TC-32 and A673 cells electroporated with siRF1 or siBP2 was effected through downregulation of EWS-Fli1, and was not the result of electroporation or non-specific effects of siRNA.
The effect of EWS-Fli1 on fenretinide-induced cell death was also investigated using FACs analysis of annexin V-PI stained cells (Figure 2d ). Electroporation of TC-32 cells with siRF1 had no significant effect on the viable cell population compared to siCON, treatment of these cells with fenretinide (1.5 mM; 24h) significantly induced death in control (55%; Po0.05), buffer (64%; Po0.05) and siCON (68%; Po0.05), or siBP2 (69%; Po0.05)-electroporated cells. However, fenretinide failed to induce cell death in siRF1-electroporated TC-32 cells. Similarly, no significant difference in cell viability was observed between A673 cells electroporated with buffer, siCON, siRF1 or siBP2 (Figure 2d ). Treatment of A673 cells with fenretinide significantly increased the non-viable cell population in control untreated cells (47%; Po0.05), cells electroporated in buffer (50%; Po0.05) and with siCON (49%; Po0.05), but not in cells electroporated with siRF1 or siBP2 (Figure 2d ). Importantly, decreased expression of EWS-Fli1 in A673 and TC-32 cells did not induce apoptosis demonstrated by FACs analysis of annexin V and PI-labelled cells over the time course studied (Table 1) . Proliferation in control, buffer and siCON-electroporated cells was not significantly different, however, electroporation of TC-32 cells with siRF1 significantly decreased proliferation (Po0.001; Figure 2e ). This decrease in proliferation was not directly responsible for the decreased sensitivity of ESFT cells to fenretinide-induced cell death since confluent growth arrested ESFT cells were as sensitive to fenretinide-induced cell death as ESFT cells under normal exponential growth conditions (Figure 2f ). TTC-466 cells (which express EWS-ERG) were more susceptible to electroporation-induced cell death than the EWS-Fli1 expressing TC-32 and A673 cells; electroporation of cells alone increasing the non-viable cell population to 32-35% (Po0.05; Figure 2d ; Table 1 Decreased EWS-Fli1 expression has no effect on fenretinide-induced ROS We have demonstrated previously that the rapid and sustained elevation of reactive oxygen species (ROS) following treatment with fenretinide is associated with the induction of cell death in ESFT cells (Myatt et al., 2005) . We therefore hypothesized that the decreased expression of EWS-Fli1 by siRNA may reduce the level of ROS produced following exposure to fenretinide. The relationship between ROS and cell death was assessed by comparing the amount of fenretinideinduced cell death (0-6 mM; 24 h) with the level of ROS . However, there was no correlation between levels of ROS and induction of cell death between ESFT cell lines. As anticipated, electroporation of all three cell lines in buffer or with siCON had no effect on induction of ROS following exposure to fenretinide (0.7-6 mM; Figure 3b ). Critically, production of ROS was unchanged in cells with reduced EWSFli1 expression following electroporation with siRF1 or siBP2 (P>0.05; Figure 3b ) although cell death was reduced. In cells with decreased EWS-Fli1 expression there was no correlation between ROS elevation and cell death (TC-32, P ¼ 0.166; A673, P ¼ 0.874).
EWS-Fli1 modulates fenretinide-induced phosphorylation of p38 MAPK and JNK p38 MAPK and JNK are stress-activated kinases associated with the induction of apoptosis in response to stress stimuli such as ceramide (Won and Singh, 2006) , ROS (Takeda et al., 2003) and anti-cancer agents (Johnson and Lapadat, 2002; Ueda et al., 2002) . Moreover, inhibition of p38 MAPK has previously been demonstrated by our laboratory to attenuate basic fibroblast growth factor (bFGF; Williamson et al., 2004) and fenretinideinduced cell death (Myatt et al., 2005) , suggesting that this kinase is a critical effector of cell death in ESFT. Therefore, expression and phosphorylation of p38 MAPK and JNK following treatment with fenretinide was determined in siRNA-treated cells.
An increase in p38 MAPK phosphorylation was observed in TC-32, A673 and TTC-466 cells within 2 h treatment with fenretinide (1.5 mM; 0-6 h; Figure 4) ; phosphorylation of JNK was observed 4 h following initial exposure to fenretinide, consistent with our previous observations (Myatt et al., 2005) . Electroporation of all cell lines with siCON, siRF1 or siBP2 had no effect on the basal levels of p38 MAPK and JNK expression or phosphorylation (Figures 4a and b) , similarly the electroporation of A673, TC-32 and TTC-466 cells with siCON (100 nM) had no effect on fenretinide-induced phosphorylation of p38 MAPK or JNK. However, electroporation of TC-32 or A673 cells with siRF1 (100 nM) reduced p38 MAPK and JNK phosphorylation following treatment with fenretinide; similarly electroporation of A673 cells with siBP2 (100 nM) abrogated fenretinide-induced p38 MAPK and JNK phosphorylation. In contrast, the electroporation of TTC-466 cells with either siBP2 or siRF1 (100 nM) had no effect on the phosphorylation of p38 MAPK or JNK following exposure to fenretinide upto 6 h ( Figure 4c ). These observations suggest that fenretinide-induced phosphorylation of p38 MAPK is at least in part dependent on EWS-Fli1 expression. Pretreatment of A673 or TC-32 cells with the p38 MAPK inhibitor SB202190 (5.6 mM; 1 h) had no effect on fenretinideinduced phosphorylation of JNK (Figure 4d ), demonstrating this to be independent of phosphorylation of p38 MAPK . As we have reported previously that p38 MAPK but not JNK activity is required for the induction of cell death by fenretinide in ESFT cells (Myatt et al., 2005) and here, we demonstrate that fenretinide does not induce phosphorylation of p38 MAPK in cells with decreased EWSFli1 expression, we went on to investigate the role of p38 MAPK in activation of the death cascade following treatment of ESFT cells with fenretinide.
p38
MAPK -dependent mitochondrial depolarization and cytochrome c release We have reported previously that treatment of ESFT cells with fenretinide induces a dose-dependent increase in mitochondrial depolarization and release of cytochrome c into the cytoplasm (Myatt et al., 2005) . In this study, we have shown that pretreatment of TC-32, SK-ES1 and RD-ES cells, which express EWS-Fli1, with the p38 MAPK inhibitor SB202190 (5.6 mM; 1h) or the antioxidant vitamin C (100 mM; 1 h) attenuated this fenretinide-induced mitochondrial depolarization (Figure 5a ). Furthermore, fenretinide-induced (1.5 mM, 24 h) release of cytochrome c into the cytoplasm was inhibited by pretreatment with the p38 MAPK inhibitor SB202190 (5.6 mM; 1 h), consistent with the hypothesis that cytochrome c release is also dependent on phosphorylation of p38 MAPK (Figure 5b ). To support the role of p38 MAPK -dependent mitochondrial depolarization in fenretinide-induced cell death, the effect of bongkrekic acid, an inhibitor of the adenine nucleotide transporter (ANT), which is a critical component of the mitochondrial permeability EWS-Fli1 and response of ESFT to fenretinide SS Myatt and SA Burchill pore, on fenretinide-induced cell death was evaluated. Bongkrekic acid (50 mM; 1 h pretreatment) decreased fenretinide-induced (1.5 mM; 24 h) cell death in SK-ES1 and TC-32 cells, but not RD-ES cells (Table 2) . Failure of bongkrekic acid to rescue RD-ES cells from fenretinide-induced cell death suggests that mitochondrial depolarization is induced by mechanisms independent of the permeability transition pore, such as Bcl-2 family member protein-dependent pore formation in the outer mitochondrial membrane, or that pore depolarization of the mitochondria is not an important effector of fenretinide-induced death in RD-ES cells. However, the inhibition of mitochondrial permeabilization by SB202190 strongly implicates this pathway in the induction of cell death following exposure to fenretinide.
Fenretinide-induced cleavage of caspases-3 and -9 is p38 MAPK -dependent and reduced by EWS-Fli1 knock down Further evidence that p38
MAPK is a critical mediator of fenretinide-induced cell death in ESFT, and that EWSFli1 expression modulates the death-inducing activity of fenretinide was obtained from investigating the effect of p38 MAPK inhibition and EWS-Fli1 targeting siRNA on cytochrome c release, caspase activation and poly (ADP ribose) polymerase (PARP) cleavage. Knock down of EWS-Fli1 expression by siRF1 significantly reduced fenretinide-induced cytochrome c release in TC-32 and A673 cells; in contrast, siRF1 had no effect on cytochrome c release in TTC-466 cells (Figure 6a ). Consistent with a reduction in fenretinideinduced mitochondrial stress, depolarization of the .05. One-way ANOVA was undertaken for each cell line, followed by Dunnett's multiple comparison post hoc test between untreated and treated samples, *Po0.05. (b) RD-ES, SK-ES1 and TC-32 cells were pretreated with SB202190 (5.6 mM; 1 h) followed by treatment with fenretinide (1.5 mM; 24 h) or ethanol (1.1% v/v; 24 h). Cell fractions were prepared and cytochrome c release determined by western blot; b-tubulin was used as a loading control. Representative of three independent experiments. À ¼ vehicle treated, þ ¼ treated with fenretinide (1.5 mM), SB202190 (5.6 mM) or vitamin C (100 mM). 
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Cleavage of caspase-3 was observed by western blot within 8-10 h of fenretinide treatment ( Figure 6c ) consistent with the activation of apoptosis. Cleavage of caspase-3 and -9 was also detected by FACs analysis, and the effect of siRNA targeting EWS-Fli1 examined. As anticipated, fenretinide-induced cleavage of caspase-3 and -9 in controls. However, fenretinide-induced cleavage of caspase-3 (Po0.05) and caspase-9 (Po0.05) was significantly reduced in TC-32 cells electroporated with siRF1 (Figure 6d) . Cleavage of caspase-3 and -9 was 
EWS-Fli1 and response of ESFT to fenretinide SS Myatt and SA Burchill fenretinide-induced cell death, vitamin C and SB202190, but not bongkrekic acid prevented caspase-3 and PARP cleavage in RD-ES cells.
Discussion
In this study, we demonstrate for the first time that EWS-Fli1 increases the sensitivity of ESFT cells to fenretinide-induced cell death through a p38 MAPK dependent mechanism. Furthermore, p38
MAPK activity is required for fenretinide-induced activation of a death cascade that is dependent on mitochondrial depolarization, cytochrome c release and caspase-3 cleavage. These data support the hypothesis that activation of p38 MAPK by fenretinide is dependent on the expression of EWSFli1, and that EWS-Fli1 may modulate the response of ESFT cells to stress.
Decreased EWS-Fli1 expression by two different siRNAs reduced the in vitro efficacy of fenretinideinduced death; critically EWS-Fli1 targeting siRNA had no effect in TTC-466 cells that express EWS-ERG confirming the specificity of these siRNAs. Interestingly, although A673 and TC-32 cells both express EWS-Fli1 type 1 siBP2 was not effective at silencing EWS-Fli1 expression in both cell lines, reflecting the multiple variables that contribute to the efficiency of gene expression knock down using siRNA. For example, mRNA secondary structure may significantly influence siRNA efficiency (Mittal, 2004) , as may point mutations at sites distal to that targeted by the siRNA (Westerhout et al., 2005) . Consistent with previous reports (Matsunobu et al., 2006) decreased expression of EWS-Fli1 did not increase the basal level of cellular apoptosis, but did cause cell cycle arrest and decreased proliferation. The lack of apoptosis may reflect the time course over which the experiments have been conducted (within 40 h of electroporation), compared to other studies where an increase in apoptotic cells has been reported within 48 h of electroporation (Chansky et al., 2004) , or 144 h posttransfection (Prieur et al., 2004) . Importantly, the decreased sensitivity of ESFT cells with low or absent EWS-Fli1 cannot be explained by growth arrest since fenretinide-induces cell death in growth arrested confluent ESFT cells as efficiently as in cells under exponential growth.
We have reported previously that the ROS-dependent phosphorylation of p38 MAPK is required for fenretinideinduced cell death in ESFT (Myatt et al., 2005) , consistent with the hypothesis that induction of ROS is responsible for the selectivity of fenretinide for malignant cells (Asumendi et al., 2002; O'Donnell et al., 2002) . The induction of ROS by fenretinide within an ESFT cell line, but not across ESFT cell lines, correlates with the degree of cell death observed following exposure to fenretinide. The lack of correlation between ROS levels and induction of cell death between cell lines is likely to reflect the anti-oxidant capacity of the individual cells. However, in ESFT cells with low or absent EWS-Fli1 there was also no relationship between ROS production and fenretinideinduced cell death. These observations suggest that EWS-Fli1 modulates the response of ESFT cells to fenretinide downstream of ROS production. This may be effected through EWS-Fli1-dependent modulation of the antioxidant capacity of the cell. However, decreased expression of EWS-Fli1 prevented fenretinide-induced phosphorylation of p38 MAPK , suggesting that EWS-Fli1 modulates the activity of p38 MAPK consistent with the hypothesis that p38 MAPK is a critical effector of fenretinide-induced cell death in ESFT (Myatt et al., 2005) . Knock down of EWS-Fli1 expression did not significantly reduce ESFT cell death following treatment of cells with 10 mM fenretinide, suggesting high levels of ROS induced cell death independently of EWS-Fli1. Loss of fenretinide-dependent phosphorylation of JNK was also observed in cells with decreased EWS-Fli1 expression, although this was independent of p38 MAPK and occurred 4 h after initiation of cell death by fenretinide in a subset of ESFT cells (Myatt et al., 2005) . Phosphorylation of JNK has also been observed in neuroblastoma cells during fenretinide-induced death (Osone et al., 2004) , although its role in the propagation of the fenretinide-induced death cascade is not clear. The decreased phosphorylation of both JNK and p38 MAPK using siRNA for EWS-Fli1 suggests that . One-way ANOVA was undertaken for each cell line, followed by Dunnett's multiple comparison post hoc test between untreated and treated samples, *Po0.05. (e) SK-ES1, TC-32 and RD-ES were pretreated with SB202190 (5.6 mM; 1 h), vitamin C (100 mM; 1 h), or bongkrekic acid (100 mM; 1 h) before incubation with fenretinide (1.5 mM; 24 h). PARP and caspase-3 cleavage were determined by western blot; btubulin was used as a loading control. Blots are representative of three independent experiments. À ¼ vehicle treated, þ ¼ treated with fenretinide (1.5 mM), SB202190 (5.6 mM), bongkrekic acid (100 mM) or vitamin C (100 mM).
EWS-Fli1 and response of ESFT to fenretinide SS Myatt and SA Burchill EWS-Fli1 may modulate an upstream MEKK, such as the redox-regulated ASK-1 (Tobiume et al., 2001; Takeda et al., 2003) , which regulates MEK-4/7 and MEK-3/6 respectively, and may be mediated by an increase in phosphatase PP5 (Huang et al., 2004) . We are currently testing this hypothesis. Enhanced levels of stress kinase activity have previously been associated with increased sensitivity of transformed cells to cytotoxics (Benhar et al., 2001) , consistent with the p38 MAPK -dependent modulation of ESFT cell sensitivity to fenretinide. However, in contrast, one study has shown that decreased expression of EWS-Fli1 increases sensitivity to etoposide and actinomycin D (Yi et al., 1997) . This suggests that EWS-Fli1 may regulate an element of the death cascade that is important for the induction of fenretinide-induced cell death (we propose this may be p38 MAPK ), but not induction of cell death by etoposide or actinomycin D. Such observations are consistent with distinct mechanisms for induction of cell death by fenretinide and conventional cytotoxics.
The critical role of p38 MAPK in fenretinide-induced cell death in ESFT is supported by its importance in regulating induction of mitochondrial depolarization and caspase-3 cleavage, and the loss of cytochrome c release and mitochondrial depolarization following fenretinide treatment in EWS-Fli1 knockdown cells. p38 MAPK has previously been reported to induce mitochondrial depolarization through recruitment of pro-apoptotic Bcl-2 family members to the outer mitochondrial membrane (Horbinski and Chu, 2005) . Furthermore, Bid truncation and Bax translocation have been observed during fenretinide-induced cell death (Boya et al., 2003; Corazzari et al., 2005) , and p38 MAPK has been reported to effect fenretinide-induced cell death in head and neck squamous cell carcinoma through induction of mitochondrial depolarization (Kim et al., 2006) . The inhibition of the permeability transition pore component ANT by bongkrekic acid significantly reduced cell death in two of three ESFT cell lines, suggesting that mitochondrial depolarization via the permeability transition pore was also important for the execution of cell death in ESFT. However, RD-ES cells were not rescued from fenretinide-induced cell death by bongkrekic acid, suggesting that fenretinide may induce membrane permeabilization through several mechanisms. The loss of Dc m was also ROS-dependent; however, as inhibition of p38 MAPK has no effect on the production of ROS (Myatt, unpublished observation) , and EWS-Fli1 knockdown had no effect on ROS, we predict that p38 MAPK may induce membrane permeabilization. The reduction in fenretinide-induced cleavage of caspases observed in EWS-Fli1 knockdown cells is also consistent with caspase activation being dependent upon the phosphorylation status of p38 MAPK and EWSFli1 expression. Furthermore, inhibition of caspase-3 and PARP cleavage following treatment of cells with vitamin C, SB202190 and bongkrekic acid, suggest that fenretinide-induced cell death is executed through a hierarchical death cascade that proceeds through the elevation of ROS, phosphorylation of p38 MAPK , mitochondrial permeabilization and caspase cleavage.
In summary, we have identified the stress-activated kinase p38
MAPK as a critical regulator of cell fate in response to the novel chemotherapeutic agent fenretinide in ESFT. The regulation of the stress kinase cascade by EWS-Fli1 and the ability of ESFT cells to tolerate elevated ROS in the absence of p38 MAPK activity demand further study. The modulation of ESFT sensitivity to fenretinide-induced cell death following decreased expression of EWS-Fli1 may also have important implications for the development of novel therapeutics.
Materials and methods

Materials
Fenretinide (N-(4-Hydroxyphenyl) retinamide) was a gift from the National Cancer Institute and stored protected from light as a 10 mM stock in ethanol (BD Biosciences, Cowley, Oxford, UK) at À201C. Bongkrekic acid (1 mM in ddH 2 O; SigmaAldrich Company Ltd, Poole, Dorset, UK) and SB202190 (200 mg/ml in DMSO, Calbiochem, Chemicon Europe Ltd, Hampshire, UK) were stored at À201C. The antioxidant vitamin C was prepared fresh as a 10 mM stock solution in ddH 2 O. Cell culture and cell lines were as described previously (Myatt et al., 2005) .
siRNA design siBP1 (sense 5 0 -GGCAGCAGAACCCUUCUUAdCdG-3 0 ) and siBP2 (sense 5 0 -GCUACGGGCAGCAGAACCCdTdT-3 0 ) targeted the EWS-Fli1 type 1 breakpoint, and siRF1 (sense 5 0 -GUACCCUUCUGACAUCUCCdTdT-3 0 ) targeted the Fli1 region of EWS-Fli1. These siRNA have been reported to reduce EWS-Fli1 expression in vitro (Dohjima et al., 2003; Chansky et al., 2004; Prieur et al., 2004) , and siBP2 has been reported to reduce ESFT growth in vivo (Hu-Lieskovan et al., 2005b) . A scramble siRNA (siCON) (Silencer Negative control #1, Ambion, Texas, TX, USA) and TTC-466 cells (which express EWS-ERG) were included as controls to test the specificity of siRNAs and the effect of electroporation in all siRNA experiments. Electroporation Cells (6 Â 10 6 ) were resuspended in 400 ml of media and transferred to an electroporation cuvette (Gene pulser cuvette 0.4 cm, Bio-Rad Laboratories Ltd, Hertfordshire, UK). siRNA (100 nM) was added, mixed by gentle pipetting and cells electroporated at 0.4 kV with a high capacitance of 500 mF (Gene pulser II, Bio-Rad Laboratories Ltd, Hertfordshire, UK). Cells were electroporated with siRNA 16 h before treatment.
Cell viability and proliferation
Viable and apoptotic cell number was determined by the trypan blue-exclusion assay and the Annexin V-propidium iodide assay as described previously (Myatt et al., 2005) . Cells were seeded into six-well plates (Primeria/BD Biosciences) and left overnight to adhere. Fenretinide (1.5 mM) or vehicle control (1.1% v/v ethanol) was added 24 h before cells were harvested by trypsinization and resuspended in appropriate media. Adherent and floating cells were included in the viability assays. The effect of fenretinide on cells at different confluency was evaluated using the trypan blue-exclusion assay. Cells were seeded at 2 Â 10 5 , 1 Â 10 6 or 1.5 Â 10 6 in six-well plates, allowed to adhere for 24 h and treated with fenretinide (3 or 10 mM) for EWS-Fli1 and response of ESFT to fenretinide SS Myatt and SA Burchill
